SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Steensma DP, Tefferi A. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk Res. 2003; 27: 95-120.
  • 2
    Sekeres MA. The epidemiology of myelodysplastic syndromes. Hematol Oncol Clin North Am. 2010; 24: 287-294.
  • 3
    Sekeres MA, Schoonen WM, Kantarjian H, et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst. 2008; 100: 1542-1551.
  • 4
    Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008; 111: 86-93.
  • 5
    Emanuel PD, Wang Z, Cai D, et al. TLK199 (Telintra™), a novel glutathione analog inhibitor of GST P1–1, causes proliferation and maturation of bone marrow precursor cells and correlates with clinical improvement in myelodysplastic syndrome (MDS) patients in a phase 2a Study. Blood. 2004; 104:Abstract 2372.
  • 6
    Stofega M, Hsu S-C, Chew J, et al. TLK199 induced apoptosis in human leukemia cells. Proc AACR Annual Meeting 2008; 49: Abstract 2270.
  • 7
    Raza A, Galili N, Smith S, et al. Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome. Blood. 2009; 113: 6533-6540.
  • 8
    Raza A, Galili N, Callender N, et al. Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra®, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome. J Hematol Oncol. 2009; 2: 20.
  • 9
    Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006; 108: 419-425.
  • 10
    Mrózek K, Heerema N, Bloomfield C. Cytogenetics in acute leukemia. Blood Rev. 2004; 18: 115-136.
  • 11
    Bernasconi P. Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review. Br J Haematol. 2009; 142: 695-708.
  • 12
    Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89: 2079-2088.
  • 13
    NCI Common Terminology Criteria for Adverse Events. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Bethesda, Md: CTEP; 2006.
  • 14
    Prebet T, Gore SD, Esterni B, et al. Outcome of patients (pts) treated for myelodysplastic syndrome (MDS) and secondary acute myeloid Leukemia (sAML) after azacitidine (AZA) failure. Blood (ASH Annual Meeting Abstracts) 2010;116: Abstract 443.
  • 15
    Quddus F, Clima J, Seedham H, Sajjad G, Galili N, Raza A. Oral ezatiostat HCl (TLK199) and myelodysplastic syndrome: a case report of sustained hematologic response following an abbreviated exposure. J Hematol Oncol. 2010; 3: 16.
  • 16
    Frytak JR, Henk HJ, De Castro CM, Halpern R, Nelson M. Estimation of economic costs associated with transfusion dependence in adults with MDS. Informa Healthcare. 2009; 25: 1941-1951.
  • 17
    Laborde E. Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death. Cell Death Differ. 2010; 17: 1373-1380.